Yahoo Web Search

  1. To keep the lesson grounded in practicality, we’ll use ROE to better understand Merck & Co., Inc. (NYSE:MRK). Merck has a ROE of 23%, based on the last twelve months ...

  2. This could indicate that investors who seek to profit from falling equity prices are not currently targeting MRK.

  3. Versum Sticks With Merger Plan as German Merck Barges In

    Bloomberg via Yahoo FinanceFeb 27 17:40 PM

    Merck’s $48-a-share offer would dismantle a proposed $3.8 billion merger between Tempe, Arizona-based Versum and Entegris Inc. The German company’s offer is 52 percent higher than ...

  4. Merck Gets CHMP Nod for Six-Week Dosing Option of Keytruda

    Zacks via Yahoo FinanceMar 05 13:42 PM

    Merck & Co., Inc. MRK announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion, recommending ...

  5. The company reversed to a profit of 2 cents per share from a loss of $1.23 per share a year ago. For 2019, the company expects sales of $255 million to $270 million. The fourth-quarter results ...

  6. ...upward momentum since a Goldman upgrade Tuesday) Ionis Pharmaceuticals Inc (NASDAQ: IONS) (in reaction to Q4 results) Inspire Medical Systems Inc (NYSE: INSP) (in reaction to Q4 results) Eli Lilly And Co (NYSE: LLY) Masimo Corporation (NASDAQ: MASI) (in reaction to Q4 results) Merck & Co., Inc.

  7. AstraZeneca/Merck's Lynparza Meets Endpoint in POLO Study

    Zacks via Yahoo FinanceFeb 27 12:15 PM

    AstraZeneca plc AZN and partner Merck’s MRK PARP inhibitor, Lynparza met the primary endpoint in a late-stage study evaluating it as first-line maintenance treatment in germline BRCA-mutated ...

  8. Doubt Grows on Celgene Deal as a Bristol-Myers Holder Balks

    Bloomberg via Yahoo FinanceFeb 28 11:37 AM

    Wellington Management Co., which manages about $1 trillion in assets, said in a news release that it “does not believe that the Celgene transaction is an attractive path” for broadening ...

  9. Stocks recently featured in the blog include: Merck MRK, Adobe ADBE, Broadcom AVGO, AstraZeneca AZN and Ross Stores ROST.

  10. Roche Holdings AG Basel ADR (OTC: RHHBY) said the FDA has accepted a sNDA for Xofluza as a single-dose oral treatment for people at high risk of complications from the flu. The sNDA is based ...